
|Articles|November 12, 2020
Pipeline: New therapies to come for debilitating eye diseases
New drug from Gensight Biologics hits pipeline
Advertisement
GenSight Biologics has developed a therapy for Leber hereditary optic neuropathy (LHON), called Lumevoq. The drug has been submitted for approval in Europe, and the company plans to submit for U.S. Food & Drug Administration approval in late 2021.
Dr. Gilly explains the mechanism of action for Lumevoq and provides a look into the GenSight Biologics pipeline for the future.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Georgia university receives state funding for state's first college of optometry
2
Practical tips and tricks: Drs Jeffrey J. Walline, Erin Tomiyama weigh in on myopia management
3
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
4
Bausch + Lomb launches preservative-free version of Blink Triple Care eye drops
5





















